Thymalin Research & Studies

Aim of the study was to identify the morphological features of reparative osteogenesis in the lower jaw bone of rats in cases of filling a bone defect with hydroxyapatite-containing osteotropic material (bone graft "Biomin GT") and injecting the surrounding soft tissues with thymalin.

Aim: The purpose of the study was to determine the features of the expression of T-lymphocytes, B-lymphocytes, macrophages in the post-traumatic regenerate of the mandible rats under conditions of filling a bone defect with hydroxyapatite-containing osteotropic material and thymalin injecting the surrounding soft tissues.

The aim of the work was a comparative study of Tocilizumab and Thymalin effects on the morphological composition and indicators of the blood clotting system in COVID-19 of middle aged and elderly patients. Severe COVID-19 patients were divided into 3 groups: 1st - control (basic therapy), 2nd - basic therapy +Tocilizumab, 3rd - basic therapy +Thymalin. Hospital mortality in COVID-19 patients after standard therapy, Tocilizumab and Thymalin application was 40,9; 28,4 and 20,6% accordingly. The number of platelets increased by 1,5 times, the concentration of fibrinogen in blood decreased by 78% and activated partial thromboplastin time decreased by 9,3% in patients taking Tocilizumab. Under the influence of Tocilizumab, the platelet/white blood cell and platelet/lymphocyte ratios increased by 1,6 and 1,4 times, which may be a predictor of an unfavorable outcome of COVID-19. Thymalin increased the number of lymphocytes and monocytes by 2 times, the number of leukocytes - by 1,3 times, the number of platelets in the blood - by 1,5 times. Thymain decreased the platelet/lymphocyte and neutrophil/lymphocyte ratios by 1,4 times and 2 times. The use of Thymalin decreased the level of fibrinogen, lactate dehydrogenase and D-dimer in the blood by 1,2; 1,8 and 1,7 times, respectively. Thymalin, compared with Tocilizumab, meets the principles of pathogenic therapy for severe COVID-19 of middle aged and elderly patients to a greater extent, having a normalizing effect on the morphological composition and indicators of the blood clotting system.

Pronounced antitumor effect of Thymalin in doses lower than the therapeutic doses was shown in experiments on albino outbred male rats with transplanted sarcoma 45. Tumor growth arrest and its regression were observed in more than half of animals and in other cases, the growth was suppressed by 78%. Microstructural changes in the thymus were analyzed. Significant increase in lymphoproliferative activity and the content of tissue basophils and plasmocytes in the thymus lobules was observed. Tumor regression was accompanied by the development of stable antistress adaptation reactions of calm and elevated activation. High efficiency of Thymalin can be attributed to the use of lower doses of the substance and their modulation during the treatment course in accordance with the regimes of activation therapy.

We studied the appearance of immunomodulator thymalin in human respiratory organs during early embryogenesis. Thymalin accumulated in young cells of airway epithelium. In the alveolar part thymalin-positive cells were diffusely spread. Mature T cells (CD3+) and the main regulatory elements (CD4+ and CD8+) were detected during the same period in the lungs in the absence of thymic microenvironment. The function of immune elements forming in fetal lungs is local protection of the fetus from potentially aggressive maternal cells and infectious agents entering the body through the trachea and fetal blood vessels.

Researchers of the St. Petersburg Institute of Bioregulation and Gerontology of the North-Western Branch of the Russian Academy of Medical Sciences and the Research Institute of Gerontology of the Ukrainian Academy of Medical Sciences (Kiev) clinically assessed the geroprotective effects of thymic and epiphyseal peptide bioregulators (Thymalin and Epithalamin, correspondingly) in 266 elderly and older persons during 6-8 years (the bioregulators were applied for the first 2-3 years of observation). The obtained results convincingly confirmed the ability of the bioregulators to normalize the basic functions of the human organism, i.e. to improve the indices of the cardiovascular, endocrine, immune, and nervous systems, homeostasis, and metabolism. The restoration of homeostasis in the patients was accompanied by a 2.0-2.4-fold decrease in acute respiratory disease incidence, reduced incidence ischemic heart disease clinical manifestations, hypertension, deforming osteoarthrosis, and osteoporosis, as compared to the control group. Such a significant improvement in the somatic state of the peptide-treated patients corresponded to a decrease in their mortality rate during the observation period: 2.0-2.1-fold among the Thymalin-treated patients, 1.6-1.8-fold--in the Epithalamin-treated group, and 2.5-fold--in the patients treated with Thymalin combined with Epithalamin, as compared to the control group. A separate group of patients was treated with Thymalin combined with Epithalamin annually for 6 years. We registered a 4.1-fold mortality decrease in this group as compared to the control level. The results of our research confirmed the conclusion on the high geroprotective efficacy of Thymalin and Epithalamin and the expediency of their application in medicine and social care as the means of health maintenance and age-related pathology prevention in persons over 60 years old enabling the prolongation of the active period of their lives.

Immunomorphological analysis revealed the presence of thymalin in human epidermis and in fetal reticuloepithelium. These structures are developed from the common embryonic primordium ectoderm. In embryos and adult humans thymalin is present only in young epidermal cells, which undergo age-related involution. By the age of 70 years, the layer of thymalin-containing cells looks thinned and discontinuous. The content of thymalin, a thymic factor, decreases with age.

Overall, fifteen patients with stage IB-2A (stages 1.5 to 2.5 as per UPDRS scale) idiopathic parkinsonism who ranged from 45 to 72 years old were examined before and after the course of treatment with thymalin. A positive time-related course was noted of the patients' general physical/mental well-being, parkinsonian triad of symptoms (tremor, rigidity, hypokinesia) associated with objective parameters characterizing the state of cerebral integrative functions (by the method of determining the biological age of the central nervous system). Efficacy of thymolin use is confirmed by EEG mapping; there has been established a significant decrement in the power of alpha rhythm in the anterocentral regions of the brain, which fact suggests to us an improvement in the cortical neurodynamics.

Thymalin, which is a polypeptide preparation from thymus, exhibited hypolipidemic and antiatherosclerotic actions in rabbits maintained on a cholesterol-containing diet during three months. At the same time, thymalin caused favourable effect on the functional activity of lymphocytes impaired in hyperlipidemic animals, i.e. it normalized the T-suppressor activity and sensitivity to atherogenic lipoproteins.

Nonspecific adhesiveness of lymphocytes to polyacrylonitrile fiber and the antigen-specific adhesiveness of T-lymphocytes to Shigella flexneri pellicular immunosorbent have been studied in dysentery patients. Short courses of treatment with indomethacin, but not with thymalin (the preparation of thymic hormones), used for immunomodulation, have accelerated the normalization of nonspecific lymphocyte adhesiveness during regression of the disease, while indomethacin, in contrast to thymalin, inhibits antigen-specific T-lymphocyte adhesiveness which increases with the development of immune response.

The effects of thymus ablation and injection of thymalin on the blood plasma kallikrein-kinin system were studied. Thymus ablation was followed by activation of kinin formation, evidenced by an elevation of the total kallikrein activity and drop of the kininogen level. Injection of thymalin into thymectomized animals makes the characteristics under study return to normal.

A clinical study of the thymus preparation Thymalin was carried out in 23 patients with special reference to its use for prevention and treatment of infectious complications of critical traumas. The complex treatment can improve the clinical course of the trauma disease and normalize immune indices of the patients.